Relapsing-remitting multiple sclerosis (RRMS) is the most common form of MS, accounting for about 85% of all diagnoses. It follows a pattern of flare-ups, called relapses, where new neurological symptoms appear or existing ones worsen, followed by periods of partial or full recovery. Most people with RRMS are diagnosed in their mid-30s, and women are affected about twice as often as men.
What Happens Inside the Body
MS is driven by the immune system mistakenly attacking the central nervous system. Specifically, immune cells cross into the brain and spinal cord and damage myelin, the insulating coating around nerve fibers. Myelin works like the rubber casing on an electrical wire. When it’s stripped away, nerve signals slow down, misfire, or stop entirely. In some cases, the nerve fibers themselves are permanently lost.
The damage zones, called lesions, contain a mix of immune cells. The most abundant are a type of white blood cell called CD8+ T cells, along with activated immune cells that clean up debris. B cells also play a significant role by producing antibodies found in the spinal fluid, a hallmark finding in MS that correlates with disease severity. In RRMS specifically, researchers have found elevated levels of a particular subset of immune cells (Th17 cells) in both the blood and spinal fluid compared to people with progressive forms of the disease, which may help explain why the relapsing-remitting pattern behaves differently from steadily worsening MS.
What a Relapse Looks and Feels Like
A relapse is defined as a new or worsening neurological symptom that lasts longer than 24 hours and isn’t caused by fever or infection. Relapses vary widely in what they affect and how severe they are. Some are mild and manageable, while others can be disabling.
In a large U.S. survey of 447 people with RRMS, the most commonly reported symptoms were:
- Fatigue: 80% of respondents
- Difficulty balancing or walking: 73%
- Numbness: 64%
- Pain: 52%
- Difficulty remembering: 52%
Fatigue in MS is not ordinary tiredness. It can be overwhelming and disproportionate to activity level, and it’s the single most common complaint. Cognitive difficulties, sometimes called “brain fog,” affect more than half of people with RRMS and can include trouble with memory, concentration, and processing speed.
Recovery After a Relapse
The “remitting” part of RRMS means symptoms partially or fully improve between attacks. During remission, the body repairs some of the myelin damage, and inflammation subsides. But recovery is not always complete. A systematic review and meta-analysis found that incomplete recovery from relapses is common and contributes to gradual disability accumulation over time.
The strongest predictor of whether you’ll fully recover from a relapse is the severity of that relapse itself. Severe attacks carried odds ratios for incomplete recovery ranging from 2.4 to 17.2, meaning the worse the flare-up, the more likely some lasting deficit will remain. Other factors like age, sex, and disease duration were less consistently linked to recovery outcomes. For people who do not receive treatment, a second clinical attack typically occurs within the first two years of disease onset.
How RRMS Is Diagnosed
Diagnosis relies on the McDonald criteria, most recently updated in 2024. The core requirement is demonstrating that damage has occurred in more than one area of the central nervous system and at more than one point in time. MRI is the primary tool, revealing characteristic lesions in the brain and spinal cord.
The 2024 revisions expanded the criteria in meaningful ways. The optic nerve can now count as a fifth anatomical location for establishing that damage is spread across different areas, which wasn’t the case before. Newer MRI features, including the “central vein sign” and “paramagnetic rim lesions,” can now provide supporting evidence. A specific antibody measurement in spinal fluid (kappa free light chains) can also help confirm the diagnosis in certain situations. These updates allow for earlier and more confident diagnosis.
Tracking Disease Activity Over Time
Beyond MRI scans and clinical exams, a blood test measuring neurofilament light chain (NfL) is becoming an increasingly useful monitoring tool. NfL is a structural protein released from damaged nerve fibers. When levels spike in the blood, it signals active nerve damage, even before symptoms appear.
During a relapse, NfL levels rise and then return close to baseline if recovery goes well. If levels stay elevated after a relapse, it suggests ongoing nerve damage and is associated with worse outcomes, more disability progression, and brain shrinkage over time. This pattern can flag aggressive disease or an early transition toward progressive MS. NfL levels also drop in response to effective treatment, making the test useful for gauging whether a therapy is working. People on high-efficacy treatments show reduced NfL levels even when they feel clinically stable, indicating less nerve damage happening beneath the surface.
Long-Term Outlook and Progression
A major concern for anyone with RRMS is the possibility of transitioning to secondary progressive MS (SPMS), where disability gradually worsens with or without relapses. The likelihood of this transition depends heavily on treatment. In natural history studies conducted before modern therapies were widely available, more than 90% of people followed for over 25 years eventually transitioned to the progressive phase, and it took roughly 15 years from disease onset on average.
More recent data tells a different story. In treated populations, the median time to SPMS from disease onset is about 32 years, with roughly 60% of people transitioning by that point. One study of 517 patients receiving disease-modifying therapy found that only 18% progressed to SPMS after a median of nearly 17 years. These numbers reflect a meaningful shift: modern treatment substantially delays and, for many people, prevents the transition to progressive disease.
Treatment Goals and Approach
The primary treatment strategy for RRMS is disease-modifying therapy, or DMT. These medications work by suppressing or modulating the immune system’s attack on the nervous system. The goal is reducing relapses, preventing new brain lesions, and slowing disability accumulation. There are now more than a dozen approved options spanning several drug classes, taken as pills, injections, or infusions.
Treatment effectiveness is measured by a concept called NEDA, or “no evidence of disease activity,” which means no relapses, no new MRI lesions, and no worsening disability. Achieving NEDA doesn’t mean the disease is cured, but it indicates the treatment is controlling it well. When a therapy isn’t achieving adequate control, neurologists typically escalate to a higher-efficacy option. Starting treatment early, ideally soon after diagnosis, is associated with better long-term outcomes because it limits the nerve damage that accumulates during uncontrolled inflammation.
Who Gets RRMS
RRMS affects women twice as often as men, with a female-to-male ratio of 2.0 to 1.0. Women are also diagnosed younger on average, at around age 34, compared to about 39 for men. Interestingly, this gender gap narrows with age and essentially disappears after 58: among people diagnosed after that age, the ratio is 1 to 1. Late-onset RRMS, typically defined as symptom onset after age 45, responds to the same disease-modifying therapies, with studies showing comparable outcomes in relapses and disease activity between late-onset and typical-onset groups.